Literature DB >> 21775449

Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.

Masashi Shingai1, Takeshi Yoshida, Malcolm A Martin, Klaus Strebel.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Vpu enhances the release of viral particles from infected cells by targeting BST-2/tetherin, a cellular protein inhibiting virus release. The widely used HIV-1(NL4-3) Vpu functionally inactivates human BST-2 but not murine or monkey BST-2, leading to the notion that Vpu antagonism is species specific. Here we investigated the properties of the CXCR4-tropic simian-human immunodeficiency virus DH12 (SHIV(DH12)) and the CCR5-tropic SHIV(AD8), each of which carries vpu genes derived from different primary HIV-1 isolates. We found that virion release from infected rhesus peripheral blood mononuclear cells was enhanced to various degrees by the Vpu present in both SHIVs. Transfer of the SHIV(DH12) Vpu transmembrane domain to the HIV-1(NL4-3) Vpu conferred antagonizing activity against macaque BST-2. Inactivation of the SHIV(DH12) and SHIV(AD8) vpu genes impaired virus replication in 6 of 8 inoculated rhesus macaques, resulting in lower plasma viral RNA loads, slower losses of CD4(+) T cells, and delayed disease progression. The expanded host range of the SHIV(DH12) Vpu was not due to adaptation during passage in macaques but was an intrinsic property of the parental HIV-1(DH12) Vpu protein. These results demonstrate that the species-specific inhibition of BST-2 by HIV-1(NL4-3) Vpu is not characteristic of all HIV-1 Vpu proteins; some HIV-1 isolates encode a Vpu with a broader host range.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775449      PMCID: PMC3196440          DOI: 10.1128/JVI.00626-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

2.  Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.

Authors:  Hiromi Imamichi; Tatsuhiko Igarashi; Tomozumi Imamichi; Olivia K Donau; Yasuyuki Endo; Yoshiaki Nishimura; Ronald L Willey; Anthony F Suffredini; H Clifford Lane; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

3.  Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIVTM) that is less pathogenic for pig-tailed macaques.

Authors:  David R Hout; Melissa L Gomez; Erik Pacyniak; Lisa M Gomez; Sarah H Inbody; Ellyn R Mulcahy; Nathan Culley; David M Pinson; Michael F Powers; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

4.  The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.

Authors:  S Bour; K Strebel
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

6.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

7.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

8.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

9.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach.

Authors:  Takeshi Yoshida; Sandra Kao; Klaus Strebel
Journal:  Front Microbiol       Date:  2011-02-18       Impact factor: 5.640

View more
  17 in total

1.  Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.

Authors:  Laura M Walker; Devin Sok; Yoshiaki Nishimura; Olivia Donau; Reza Sadjadpour; Rajeev Gautam; Masashi Shingai; Robert Pejchal; Alejandra Ramos; Melissa D Simek; Yu Geng; Ian A Wilson; Pascal Poignard; Malcolm A Martin; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

2.  Simian-Human immunodeficiency viruses expressing chimeric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmembrane domains in the rate of CD4(+) T cell loss in macaques.

Authors:  Autumn Ruiz; Kimberly Schmitt; Nathan Culley; Edward B Stephens
Journal:  Virology       Date:  2012-12-05       Impact factor: 3.616

3.  Generation of rhesus macaque-tropic HIV-1 clones that are resistant to major anti-HIV-1 restriction factors.

Authors:  Masako Nomaguchi; Masaru Yokoyama; Ken Kono; Emi E Nakayama; Tatsuo Shioda; Naoya Doi; Sachi Fujiwara; Akatsuki Saito; Hirofumi Akari; Kei Miyakawa; Akihide Ryo; Hirotaka Ode; Yasumasa Iwatani; Tomoyuki Miura; Tatsuhiko Igarashi; Hironori Sato; Akio Adachi
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

4.  Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Authors:  Takeshi Yoshida; Yoshio Koyanagi; Klaus Strebel
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

5.  Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.

Authors:  Chia-Yen Chen; Masashi Shingai; Sarah Welbourn; Malcolm A Martin; Pedro Borrego; Nuno Taveira; Klaus Strebel
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

6.  A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells.

Authors:  Rajesh Thippeshappa; Hongmei Ruan; Weiming Wang; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

7.  Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.

Authors:  Weitong Yao; Takeshi Yoshida; Saki Hashimoto; Hiroaki Takeuchi; Klaus Strebel; Shoji Yamaoka
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

Review 8.  HIV accessory proteins versus host restriction factors.

Authors:  Klaus Strebel
Journal:  Curr Opin Virol       Date:  2013-11-15       Impact factor: 7.090

9.  Restriction of Retroviral Replication by Tetherin/BST-2.

Authors:  Jason Hammonds; Jaang-Jiun Wang; Paul Spearman
Journal:  Mol Biol Int       Date:  2012-07-02

10.  Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.

Authors:  Kristina Nikovics; Marie-Christine Dazza; Michel Ekwalanga; Fabrizio Mammano; François Clavel; Sentob Saragosti
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.